MarketCap
Sonoma Pharmaceuticals SNOA
$ 1.22
0.81%
Facebook
X
Telegram
Sonoma Pharmaceuticals Revenue | SNOA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Sonoma Pharmaceuticals
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.5 M | 14.3 M | 12.7 M | 13.3 M | 12.6 M | 18.6 M | 18.9 M | 19 M | 16.7 M | 12.8 M | 15.1 M | 13.9 M | 13.7 M | 15.5 M | 12.7 M | 9.75 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.5 M | 9.75 M | 14.9 M |
Quarterly Revenue Sonoma Pharmaceuticals
| 2027-Q1 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.41 M | 4.35 M | 5.6 M | 4.02 M | 4.35 M | 5.6 M | 4.02 M | - | 3.56 M | 3.58 M | 3.39 M | - | 3.14 M | 2.73 M | 3.43 M | - | 2.94 M | 3.33 M | 3.98 M | - | 2.9 M | 10.3 M | 7.43 M | - | 4.94 M | 4.94 M | 5.77 M | 5.77 M | 4.68 M | 14.4 M | 9.68 M | - | 5.28 M | 5.28 M | 4.94 M | - | 4.84 M | 4.32 M | 3.84 M | - | 3.36 M | 8.8 M | 5.44 M | - | 2.48 M | 6.79 M | 7.73 M | - | 3.22 M | 9.87 M | 6.66 M | - | 3.29 M | 10.8 M | 7.46 M | - | 3.54 M | 12.1 M | 8.58 M | - | 2.79 M | 3.66 M | 2.94 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.4 M | 2.48 M | 5.46 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M |  Canada |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 4.46 | 13.78 % | $ 245 M | Canada |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 5.89 | 1.55 % | $ 2.18 B | Canada |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 0.88 | 1.04 % | $ 262 M | Canada |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.65 | 1.57 % | $ 2.79 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 7.09 | 0.27 % | $ 105 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 3.25 | 0.78 % | $ 1.25 B | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 7.24 | 14.29 % | $ 387 M | USA |
 |
Evolus
EOLS
|
297 M | $ 7.47 | 4.62 % | $ 482 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 30.58 | 0.33 % | $ 1.12 B | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 0.94 | 0.18 % | $ 89.6 M | Canada |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 1.29 | 2.19 % | $ 163 M | USA |
 |
Pacira BioSciences
PCRX
|
726 M | $ 25.05 | 0.42 % | $ 1.12 B | USA |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 14.44 | 1.3 % | $ 2 B | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 3.48 | 0.68 % | $ 137 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 8.23 | 0.93 % | $ 296 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 5.03 | 1.07 % | $ 251 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 7.06 | 3.07 % | $ 618 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.25 | 0.81 % | $ 323 M | Canada |
 |
Tilray
TLRY
|
821 M | $ 3.72 | 3.05 % | $ 3.31 B | Canada |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.01 | 1.46 % | $ 23.3 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.55 | 1.59 % | $ 37.3 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 17.62 | 0.11 % | $ 20.2 B | USA |
 |
cbdMD
YCBD
|
19.2 M | $ 0.43 | 0.29 % | $ 1.73 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |